PTCT: PTC Therapeutics, Inc.
About
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.
Current Value
$39.381 Year Return
Current Value
$39.381 Year Return
Key Details
Market Cap
$3.04B
P/E Ratio
-6.63
1Y Stock Return
80.14%
1Y Revenue Growth
12.84%
Dividend Yield
0.00%
Price to Book
-2.9
Strategies that include PTCT
Stock's related to PTCT
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| EXPO | 45.23% | $4.82B | +20.93% | 1.16% |
| DYN | 42.33% | $3.02B | +182.40% | 0.00% |
| RDNT | 40.81% | $5.91B | +151.89% | 0.00% |
| B | 39.71% | $2.38B | +80.47% | 1.37% |
| PGEN | 39.70% | $228.91M | -28.00% | 0.00% |
| XNCR | 37.13% | $1.65B | +27.73% | 0.00% |
| PEB | 36.70% | $1.48B | +0.08% | 0.33% |
| REAL | 36.49% | $473.87M | +93.72% | 0.00% |
| CTS | 36.04% | $1.58B | +33.53% | 0.30% |
| ARWR | 35.50% | $2.31B | -34.44% | 0.00% |
| RVMD | 35.49% | $9.50B | +171.62% | 0.00% |
| PRTA | 35.47% | $756.01M | -56.52% | 0.00% |
| NTLA | 35.05% | $1.44B | -50.35% | 0.00% |
| RCUS | 34.15% | $1.33B | +5.07% | 0.00% |
| CYRX | 34.12% | $342.80M | -48.82% | 0.00% |
| BCRX | 34.04% | $1.49B | +41.37% | 0.00% |
| NVCR | 34.02% | $1.78B | +34.75% | 0.00% |
| PAHC | 33.98% | $961.96M | +131.93% | 2.04% |
| WIX | 33.92% | $10.24B | +90.29% | 0.00% |
| THRM | 33.92% | $1.28B | -10.01% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MNOV | 0.04% | $93.19M | +2.15% | 0.00% |
| ARQ | 0.04% | $332.89M | +216.80% | 0.00% |
| LX | 0.04% | $446.80M | +57.07% | 4.21% |
| COP | 0.04% | $130.16B | -1.63% | 2.59% |
| GIS | -0.04% | $34.85B | -2.91% | 3.78% |
| LITB | -0.09% | $35.48M | -75.45% | 0.00% |
| XBIT | 0.09% | $203.32M | +87.36% | 0.00% |
| MESO | 0.10% | $1.23B | +347.11% | 0.00% |
| TRV | -0.12% | $58.86B | +48.10% | 1.59% |
| EDSA | 0.13% | $7.11M | -21.79% | 0.00% |
| QD | -0.13% | $335.92M | +42.44% | 0.00% |
| WHF | -0.17% | - | - | 14.53% |
| FINV | -0.18% | $909.61M | +27.93% | 3.80% |
| DXYZ | 0.23% | - | - | 0.00% |
| CSTE | 0.23% | $134.01M | +2.92% | 0.00% |
| PEP | -0.24% | $215.02B | -6.60% | 3.35% |
| TH | 0.25% | $839.02M | -24.49% | 0.00% |
| AGX | 0.25% | $2.01B | +224.91% | 0.85% |
| UTI | 0.26% | $1.07B | +73.54% | 0.00% |
| MAGN | -0.29% | $638.97M | -3.42% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HUSA | -15.76% | $16.69M | -11.56% | 0.00% |
| CME | -12.82% | $82.76B | +9.21% | 1.98% |
| ORLY | -11.62% | $69.31B | +22.06% | 0.00% |
| SHEL | -10.91% | $205.19B | -1.07% | 4.20% |
| NRDS | -10.22% | $984.08M | +21.93% | 0.00% |
| PGR | -10.16% | $149.10B | +57.29% | 0.45% |
| PULM | -10.12% | $19.83M | +202.98% | 0.00% |
| VLO | -10.07% | $44.96B | +15.30% | 2.28% |
| MPC | -10.04% | $51.04B | +7.57% | 1.57% |
| BNED | -9.44% | $277.22M | -91.94% | 0.00% |
| JNPR | -9.33% | $11.61B | +30.55% | 2.49% |
| PRPO | -9.11% | $9.10M | -13.65% | 0.00% |
| CRVO | -8.76% | $83.20M | +2.86% | 0.00% |
| PSX | -8.52% | $54.08B | +11.52% | 3.43% |
| OXBR | -7.55% | $19.05M | +178.18% | 0.00% |
| XOM | -7.36% | $521.39B | +13.56% | 3.22% |
| ACGL | -7.35% | $36.00B | +16.84% | 0.00% |
| UNM | -7.26% | $13.16B | +69.20% | 2.16% |
| CASI | -7.02% | $71.56M | -6.32% | 0.00% |
| NNE | -6.84% | $833.66M | +531.50% | 0.00% |
ETF's related to PTCT
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PBE | 52.65% | $258.53M | 0.58% |
| XBI | 50.87% | $6.58B | 0.35% |
| PTH | 48.83% | $143.31M | 0.6% |
| IBB | 47.94% | $6.66B | 0.45% |
| FBT | 47.94% | $1.11B | 0.56% |
| GNOM | 45.47% | $70.59M | 0.5% |
| XPH | 44.97% | $157.87M | 0.35% |
| RSPA | 44.52% | $273.87M | 0% |
| PINK | 42.82% | $161.15M | 0.5% |
| BBH | 42.81% | $397.87M | 0.35% |
| IWO | 41.98% | $12.56B | 0.24% |
| FXH | 41.48% | $1.15B | 0.62% |
| KOMP | 41.04% | $2.09B | 0.2% |
| IHE | 41.04% | $596.23M | 0.39% |
| IWC | 40.88% | $933.99M | 0.6% |
| VBK | 40.63% | $19.31B | 0.07% |
| QQA | 40.33% | $135.01M | 0% |
| ARKG | 39.93% | $1.13B | 0.75% |
| PBW | 39.57% | $301.18M | 0.65% |
| EFAA | 39.14% | $117.38M | 0% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| MINT | 0.04% | $11.62B | 0.35% |
| SEIX | 0.67% | $268.81M | 0.62% |
| CANE | -0.68% | $17.72M | 0.29% |
| DBMF | -0.69% | $1.02B | 0.85% |
| TPMN | 0.82% | $40.60M | 0.65% |
| FTGC | -0.86% | $2.17B | 1.02% |
| CORN | 1.03% | $61.12M | 0.2% |
| FLRN | -1.06% | $2.33B | 0.15% |
| SGOV | 1.32% | $27.53B | 0.09% |
| DBC | -1.37% | $1.39B | 0.87% |
| CLOI | 1.45% | $715.40M | 0.4% |
| PDBC | -1.49% | $4.40B | 0.59% |
| KCCA | 1.56% | $220.51M | 0.87% |
| BCI | 1.64% | $1.20B | 0.26% |
| UNG | -1.95% | $908.80M | 1.06% |
| XHLF | 1.96% | $874.27M | 0.03% |
| GBIL | 2.16% | $5.60B | 0.12% |
| JUCY | 2.25% | $324.29M | 0.6% |
| BCD | 2.45% | $245.02M | 0.3% |
| WEAT | 2.48% | $120.27M | 0.28% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -31.45% | $388.04M | 1.43% |
| VIXY | -23.67% | $195.31M | 0.85% |
| USCI | -12.33% | $185.47M | 1.07% |
| DBE | -12.23% | $50.13M | 0.77% |
| DBO | -11.93% | $217.57M | 0.77% |
| KMLM | -10.92% | $353.87M | 0.9% |
| UUP | -10.28% | $309.25M | 0.77% |
| USDU | -10.22% | $201.97M | 0.5% |
| COMT | -9.72% | $829.06M | 0.48% |
| CTA | -9.72% | $350.27M | 0.78% |
| EQLS | -9.58% | $76.08M | 1% |
| TAIL | -9.41% | $67.98M | 0.59% |
| BOXX | -9.38% | $4.43B | 0.1949% |
| DBA | -9.26% | $755.88M | 0.93% |
| XBIL | -8.51% | $637.70M | 0.15% |
| FMF | -8.21% | $244.61M | 0.95% |
| FBY | -7.76% | $127.69M | 0.99% |
| TBIL | -4.97% | $4.38B | 0.15% |
| GSG | -3.29% | $914.42M | 0.75% |
| UNG | -1.95% | $908.80M | 1.06% |
News
SeekingAlpha
Following underperformance in Q2 2024, the Franklin Biotechnology Discovery Fund returned to strength in Q3 2024. Click here to read the full commentary.
Yahoo
On Thursday, the FDA granted accelerated approval to PTC Therapeutics, Inc.’s (NASDAQ:PTCT) gene therapy for AADC deficiency, the first-ever gene therapy approved in the U.S. that is directly administered to the brain. The gene therapy, which will be marketed in the United States with the brand name Kebilidi (eladocagene exuparvovec-tneq), is indicated for the treatment of children and adults with aromatic L-amino acid decarboxylase (AADC) deficiency, including the full spectrum of disease sever
Yahoo
KEBILIDI is delivered via a precise neurosurgical procedure to the putamen of the brain.
Yahoo
Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review voucher for PTC.
Yahoo
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever gene therapy approved in the United States that is directly administered to the brain.
Yahoo
PTC Therapeutics ( NASDAQ:PTCT ) Third Quarter 2024 Results Key Financial Results Revenue: US$196.8m (flat on 3Q 2023...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.